Organic Process Research & Development 2008, 12, 23–29
Full Papers
Process Research on the Preparation of
1-(3-Trimethylsilylphenyl)-2,2,2-trifluoroethanone by a Friedel–Crafts acylation
Reaction
Richard A. Wolf*
Dowpharma, The Dow Chemical Company, 1710 Building, Midland, Michigan 48674, U.S.A.
Abstract:
should be noted.11 An earlier version of the present research
was reported in a U.S. Patent application.12
Zifrosilone (1-(3-trimethylsilylphenyl)-2,2,2-trifluoroethanone) (3)
is a cholinesterase inhibitor that has been studied for the treatment
of Alzheimer’s disease. Process research has been carried out on
a route to convert phenyltrimethylsilane to 3 by Friedel–Crafts
acylation using trifluoroacetic anhydride. Kinetics and products
analyses suggest that the optimal conditions for this reaction are
noncatalytic amounts of aluminum chloride, dichloromethane
solvent and as low a temperature as can be practically used in a
scaled-up process. Significant separation challenges to isolate 3
from the isomer byproduct 1-(4-trimethylsilylphenyl)-2,2,2-tri-
fluoroethanone) (4) remain. These challenges were investigated
using vapor–liquid equilibrium studies.
The aluminum chloride catalyzed electrophilic aromatic
substitution (trifluoroacylation-deprotonation) of arenes by
trifluoroacetic anhydride (TFAA) has recently been cited in the
literature.13–16 However, the reaction of such trimethylsilyl arenes
as phenyltrimethylsilane (1) and 1,3-bis(trimethylsilyl)benzene17–22
(2) with TFAA is not so clear-cut (Scheme 2). The trimethylsilyl
group has been known to be displaced from aromatic rings by
acyllium ions. Thus, 2 has been reacted with acetyl chloride
and aluminum chloride in carbon disulfide solvent to form
3-trimethylsilyl acetophenone in a yield of 44%.23 Another paper
cites this reaction (with acetic anhydride) as occurring with
”excellent yields”.24
Ipso substitution of 2 has been reported with dichlorometh-
ylmethyl ether and aluminum chloride (in dichloromethane
solvent) to form, after workup with water, trimethylsilyl
benzaldehydes (Scheme 1).25 The regiochemistry for the reac-
tion, however, was only 89% meta product, with 9.5% of
p-trimethylsilylbenzaldehyde also formed. Compound 2 has
been reacted with (hydroxy(tosyloxy)iodo)benzene in acetoni-
trile solvent to effect an ipso electrophilic aromatic substitution
1. Introduction
Zifrosilone (1-(3-trimethylsilylphenyl)-2,2,2-trifluoroetha-
none) (3) is a cholinesterase inhibitor that has been studied for
the treatment of Alzheimer’s disease.1–8 The preferred synthetic
method has been a bis-metalation process, starting with 1,3-
dibromobenzene and sequentially attaching the trimethylsilyl
and trifluoroacetyl groups, to form 3.9,10 A warning regarding
the potential explosiveness of 3-bromophenyllithium, a potential
byproduct in this and some other potential routes to Zifrosilone,
(11) Leleu, M. J. Cah. Notes Doc. 1977, 88, 367.
(12) Wolf, R. A. PCT Int. Appl. WO 95-US4837, April 18, 1995.
(13) Liu, K.; Xu, L.; Berger, J. P.; MacNaul, K. L.; Zhou, G.; Doebber,
T. W.; Forrest, M. J.; Moller, D. E.; Jones, A. B J. Med. Chem. 2005,
48, 2262–2265.
* To whom correspondence should be addressed. Telephone: 859 261-3743.
E-mail: wolfrap@hotmail.com.
(1) Lane, R. M.; Polymeropoulos, M. H. PCT Int. Appl. WO 2003-EP8719
20, August 6, 2003.
(2) Coe, J. W.; Sands, S. B.; Harrigan, E. P.; O’Neill, B. T.; Watsky,
E. J., U.S. Pat. Appl. 2001-760966, January 16, 2001.
(3) Tracey, K. J.; Pavlov, V. A. PCT Int. Appl. WO 2005-US3029, January
27, 2005.
(14) Mahindroo, N.; Huang, C.-F.; Peng, Y.-H.; Wang, C.-C.; Liao, C.-
C.; Lien, T.-W.; Chittimall, S. K.; Huang, W.-J.; Chai, C.-H.; Prakash,
E.; Chen, C.-P. J. Med. Chem. 2005, 48, 8194–8208.
(15) Adams, A. D.; Hu, Z.; Langen, D. von; Dadiz, A.; Elbrecht, A.;
MacNaul, K. L.; Berger, J. P.; Zhou, G.; Doebber, T. W.; Muerer, R.;
Forrest, M. J. Bioorg. Med. Chem. Lett. 2003, 13, 3185–3190.
(16) Corrie, J. E. T.; Munasinghe, V. R. N.; Rettig, W. J. Heterocycl. Chem.
2000, 37, 1447–1456.
(4) Dow, J.; Dulery, B. D.; Hornsperger, J.-M.; Di Francesco, G. F.;
Keshary, P.; Haegele, K. D. Arzneim.-Forsch. 1995, 45, 1245–1252.
(5) Cutler, N. R.; Seifert, R. D.; Schleman, M. M.; Sramek, J. J.; Szylleyko,
O. J.; Howard, D. R.; Barchowsky, A.; Wardle, T. S.; Brass, E. P.
Clin. Pharmacol. Ther. 1995, 58, 54–61.
(17) Freeburger, M. E.; Spialter, L. J. Am. Chem. Soc. 1971, 93, 1894.
(18) Clark, H. A.; Gordon, A. F.; Young, C. W.; Hunter, M. J. J. Am.
Chem. Soc. 1951, 73, 3798.
(19) Eaborn, C.; Jackson, P. M. J. Chem. Soc. B 1969, 21.
(20) Bourgeois, P.; Calas, R. J. Organomet. Chem 1975, 84, 165.
(21) Schlosser, M.; Choi, J. H.; Takagishi, S. Tetrahedron 1990, 46, 5633.
(22) Mochida, K.; Hiraga, Y; Yakeuchi, H.; Ogawa, H. Organometallics
1987, 6, 2293.
(6) Zhu, X.-D.; Giacobini, E.; Hornsperger, J.-M. Eur. J. Pharmacol. 1995,
276, 93–99.
(7) Hornsperger, J.-M.; Collard, J.-N.; Schirlin, D.; Dow, J.; Heydt, J.-
G.; Dulery, B. Alzheimer Dis. 1994, 13, 1–136.
(8) Hornsperger, J.-M.; Collard, J.-N.; Heydt, J.-G.; Giacobini, E.; Funes,
S.; Dow, J.; Schirlin, D. Biochem. Soc. Trans. 1994, 22, 758–763.
(9) Gandolfi, R.; Klipa, D. K.; Fetner, N. J. Eur. Pat. Appl EP 95-401478,
June 21, 1995.
(23) Yamakawa, T.; Kagechika, H.; Kawachi, E.; Hashimoto, Y.; Shudo,
K. J. Med. Chem. 1990, 33, 1430.
(24) Effenberger, F.; Spiegler, W. Angew. Chem., Int. Ed. Engl. 1981, 20,
265.
(10) Schirlin, D.; Collard, J.-N.; Hornsperger, J.-M. Eur. Pat. Appl. EP
89-401775, June 22, 1989.
(25) Calas, R.; Gerval, J. C. R. Acad. Sci., Paris 1987,t. 305, Series II,
1423.
10.1021/op700199p CCC: $40.75
Published on Web 01/03/2008
2008 American Chemical Society
Vol. 12, No. 1, 2008 / Organic Process Research & Development
•
23